Literature DB >> 27665290

Distinct Immunoregulatory Mechanisms in Mesenchymal Stem Cells: Role of the Cytokine Environment.

Vladimir Holan1,2, Barbora Hermankova3,4, Pavla Bohacova3,4, Jan Kossl3,4, Milada Chudickova3,4, Michaela Hajkova3,4, Magdalena Krulova3,4, Alena Zajicova3, Eliska Javorkova3,4.   

Abstract

Mesenchymal stem cells (MSCs) represent a population of cells which have the ability to regulate reactivity of T and B lymphocytes by multiple mechanisms. The immunoregulatory activities of MSCs are strictly influenced by the cytokine environment. Here we show that two functionally distinct cytokines, interleukin-4 (IL-4) and interferon-γ (IFN-γ), significantly potentiate the ability of MSCs to inhibit IL-10 production by activated regulatory B cells (Bregs). However, MSCs in the presence of IL-4 or IFN-γ inhibit the IL-10 production by different mechanisms. Preincubation of MSCs with IFN-γ led to the suppression, but pretreatment with IL-4 of neither MSCs nor B cells resulted in the suppression of IL-10 production. The search for candidate regulatory molecules expressed in cytokine-treated MSCs revealed different patterns of the gene expression. Pretreatment of MSCs with IFN-γ, but not with IL-4, induced expression of indoleamine-2,3-dioxygenase, cyclooxygenase-2 and programmed cell death-ligand 1. To identify the molecule(s) responsible for the suppression of IL-10 production, we used specific inhibitors of the putative regulatory molecules. We found that indomethacine, an inhibitor of cyclooxygenase-2 (Cox-2) activity, completely abrogated the inhibition of IL-10 production in cultures containing MSCs and IFN-γ, but had no effect on the suppression in cell cultures containing MSCs and IL-4. The results show that MSCs can inhibit the response of B cells to one stimulus by different mechanisms in dependence on the cytokine environment and thus support the idea of the complexity of immunoregulatory action of MSCs.

Entities:  

Keywords:  Cyclooxygenase 2; Cytokine environment; Gene expression; IFN-γ; IL-10; IL-4; Immunoregulation; Mesenchymal stem cells; Regulatory B cells

Mesh:

Substances:

Year:  2016        PMID: 27665290     DOI: 10.1007/s12015-016-9688-y

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  33 in total

1.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Authors:  Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

2.  Human mesenchymal stem cells modulate B-cell functions.

Authors:  Anna Corcione; Federica Benvenuto; Elisa Ferretti; Debora Giunti; Valentina Cappiello; Francesco Cazzanti; Marco Risso; Francesca Gualandi; Giovanni Luigi Mancardi; Vito Pistoia; Antonio Uccelli
Journal:  Blood       Date:  2005-09-01       Impact factor: 22.113

Review 3.  Mechanisms of mesenchymal stromal cell immunomodulation.

Authors:  Karen English
Journal:  Immunol Cell Biol       Date:  2012-10-23       Impact factor: 5.126

4.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

5.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

Review 6.  The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.

Authors:  Simone Muenst; Savas D Soysal; Alexandar Tzankov; Sylvia Hoeller
Journal:  Expert Opin Ther Targets       Date:  2014-12-10       Impact factor: 6.902

7.  A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype.

Authors:  Ruth S Waterman; Suzanne L Tomchuck; Sarah L Henkle; Aline M Betancourt
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

8.  Suppression of IL-10 production by activated B cells via a cell contact-dependent cyclooxygenase-2 pathway upregulated in IFN-γ-treated mesenchymal stem cells.

Authors:  Barbora Hermankova; Alena Zajicova; Eliska Javorkova; Milada Chudickova; Peter Trosan; Michaela Hajkova; Magdalena Krulova; Vladimir Holan
Journal:  Immunobiology       Date:  2015-09-12       Impact factor: 3.144

9.  IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells.

Authors:  Karen English; Frank P Barry; Ciara P Field-Corbett; Bernard P Mahon
Journal:  Immunol Lett       Date:  2007-04-26       Impact factor: 3.685

10.  Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens.

Authors:  D Angoulvant; A Clerc; S Benchalal; C Galambrun; A Farre; Y Bertrand; A Eljaafari
Journal:  Biorheology       Date:  2004       Impact factor: 1.875

View more
  15 in total

1.  The Impact of Morphine on the Characteristics and Function Properties of Human Mesenchymal Stem Cells.

Authors:  Vladimir Holan; Kristina Cechova; Alena Zajicova; Jan Kossl; Barbora Hermankova; Pavla Bohacova; Michaela Hajkova; Magdalena Krulova; Petr Svoboda; Eliska Javorkova
Journal:  Stem Cell Rev Rep       Date:  2018-12       Impact factor: 5.739

2.  Immunomodulatory Properties of Bone Marrow Mesenchymal Stem Cells from Patients with Amyotrophic Lateral Sclerosis and Healthy Donors.

Authors:  Eliska Javorkova; Nicole Matejckova; Alena Zajicova; Barbora Hermankova; Michaela Hajkova; Pavla Bohacova; Jan Kossl; Magdalena Krulova; Vladimir Holan
Journal:  J Neuroimmune Pharmacol       Date:  2018-09-21       Impact factor: 4.147

3.  Sertoli Cells Possess Immunomodulatory Properties and the Ability of Mitochondrial Transfer Similar to Mesenchymal Stromal Cells.

Authors:  Bianka Porubska; Daniel Vasek; Veronika Somova; Michaela Hajkova; Michaela Hlaviznova; Tereza Tlapakova; Vladimir Holan; Magdalena Krulova
Journal:  Stem Cell Rev Rep       Date:  2021-06-11       Impact factor: 5.739

4.  Crosstalk between mesenchymal stem cells and macrophages in inflammatory bowel disease and associated colorectal cancer.

Authors:  Fei Mao; Jing-Jing Kang; Xiu Cai; Ning-Feng Ding; Yun-Bing Wu; Yong-Min Yan; Hui Qian; Xu Zhang; Wen-Rong Xu
Journal:  Contemp Oncol (Pozn)       Date:  2017-06-30

5.  Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.

Authors:  Dobrin D Draganov; Antonio F Santidrian; Ivelina Minev; Duong Nguyen; Mehmet Okyay Kilinc; Ivan Petrov; Anna Vyalkova; Elliot Lander; Mark Berman; Boris Minev; Aladar A Szalay
Journal:  J Transl Med       Date:  2019-03-27       Impact factor: 5.531

Review 6.  Cytokine interplay among the diseased retina, inflammatory cells and mesenchymal stem cells - a clue to stem cell-based therapy.

Authors:  Vladimir Holan; Barbora Hermankova; Magdalena Krulova; Alena Zajicova
Journal:  World J Stem Cells       Date:  2019-11-26       Impact factor: 5.326

7.  Mesenchymal stem cells are attracted to latent HIV-1-infected cells and enable virus reactivation via a non-canonical PI3K-NFκB signaling pathway.

Authors:  Partha K Chandra; Samantha L Gerlach; Chengxiang Wu; Namrata Khurana; Lauren T Swientoniewski; Asim B Abdel-Mageed; Jian Li; Stephen E Braun; Debasis Mondal
Journal:  Sci Rep       Date:  2018-10-02       Impact factor: 4.379

Review 8.  Systematic Exposition of Mesenchymal Stem Cell for Inflammatory Bowel Disease and Its Associated Colorectal Cancer.

Authors:  Jingjing Kang; Li Zhang; Xiao Luo; Xiangyu Ma; Gaoying Wang; Yanhui Yang; Yongmin Yan; Hui Qian; Xu Zhang; Wenrong Xu; Fei Mao
Journal:  Biomed Res Int       Date:  2018-12-26       Impact factor: 3.411

9.  MSCs rescue impaired wound healing in a murine LAD1 model by adaptive responses to low TGF-β1 levels.

Authors:  Dongsheng Jiang; Karmveer Singh; Jana Muschhammer; Susanne Schatz; Anca Sindrilaru; Evgenia Makrantonaki; Yu Qi; Meinhard Wlaschek; Karin Scharffetter-Kochanek
Journal:  EMBO Rep       Date:  2020-02-21       Impact factor: 8.807

10.  Systemic Administration of Rejuvenated Adipose-Derived Mesenchymal Stem Cells Improves Liver Metabolism in Equine Metabolic Syndrome (EMS)- New Approach in Veterinary Regenerative Medicine.

Authors:  Krzysztof Marycz; J Szłapka-Kosarzewska; F Geburek; K Kornicka-Garbowska
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.